AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01569607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Training sessions for 5 days in a row
Study NCT01569607 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study NCT02978976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
Study NCT02978976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline placebo injection in the same regimen.
Study NCT00469599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
Study NCT00469599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: 1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
Study NCT01463449 — intervention group
Intervention type: PROCEDURE
Intervention: gastric bypass
Description: Low grade inflammation in adipose tissue before and after gastric bypass
Study NCT04275362 — intervention group
Intervention type: DEVICE
Intervention: DJO Empowr PS Knee System
Description: Patients will receive a DJO Empowr PS Knee System total knee replacement
Study NCT04275362 — intervention group
Intervention type: DEVICE
Intervention: Stryker Triathlon Total Knee System
Description: Patients received a Stryker Triathlon Total Knee System total knee replacement
Study NCT04275362 — intervention group
Intervention type: DEVICE
Intervention: Biomet Vanguard Complete Knee System
Description: Patients received a Biomet Vanguard Complete Knee System total knee replacement
Study NCT04275362 — intervention group
Intervention type: DEVICE
Intervention: Control
Description: No total knee replacement
Study NCT03121053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Study NCT03121053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotone saline
Study NCT00194428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almond enriched diet
Description: Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
Study NCT00194428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat caloric diet
Description: Low fat caloric diet
Study NCT02639221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331
Study NCT02639221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PXT002331
Study NCT01859624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol 4 mg
Study NCT01931566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone SR tablets
Study NCT01931566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets
Study NCT01929317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2mg tablet
Description: Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
Study NCT01929317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 8mg tablet
Description: Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
Study NCT01929317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR matching Placebo tablet
Description: Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
Study NCT03658681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fat 14.9 E%
Description: Dietary cross-over study with saturated fat
Study NCT03658681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat 13.6 E%
Description: Dietary cross-over study with polyunsaturated fat
Study NCT01297829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ibuprofen
Description: 800 mg IV ibuprofen 30 minutes preoperatively
Study NCT01297829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV normal saline
Study NCT03294252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
Study NCT03294252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Folinic acid
Description: Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
Study NCT03294252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
Study NCT02565108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/Day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT02565108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT02565108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
Study NCT02565108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobazam
Description: Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
Study NCT03278171 — intervention group
Intervention type: BEHAVIORAL
Intervention: Impact Event Scale Revisited
Description: Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
Study NCT02484885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
Study NCT00973635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs.
Study NCT00760617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2186877A
Description: Intramuscular (IM) administration, 1 dose
Study NCT00760617 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Intramuscular (IM) administration, 1 dose
Study NCT02633306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
Study NCT02873377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Gum
Description: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Study NCT02873377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Gum
Description: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
Study NCT02873377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ
Description: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Study NCT02873377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ
Description: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Study NCT02873377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Quitline Referral
Description: Fax referral to the State smoking Quitline
Study NCT02873377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Quitline Referral
Description: Fax referral to the State smoking Quitline
Study NCT02873377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and follow-up phone call
Study NCT01773213 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ice-water-test
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 3 mg
Description: JNJ-54861911 3 mg will be administered as an oral suspension formulation.
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 10 mg
Description: JNJ-54861911 10 mg will be administered as an oral suspension formulation.
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 30 mg
Description: JNJ-54861911 30 mg will be administered as an oral suspension formulation.
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 80 mg
Description: JNJ-54861911 80 mg will be administered as an oral suspension formulation.
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 25 mg
Description: JNJ-54861911 25 mg will be administered as a solid dose formulation.
Study NCT01887535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as an oral suspension formulation.
Study NCT02936596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid combination of immunosuppressive agents
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
Study NCT02936596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid
Study NCT02778789 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
Study NCT02778789 — intervention group
Intervention type: DRUG
Intervention: TNF-alpha Inhibitor
Description: Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
Study NCT01473901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + temozolomide
Description: The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
Study NCT01473901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 +temozolomide with/without radiotherapy
Description: The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
Study NCT01147874 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: lab draws and imaging
Description: 1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
Study NCT02099955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 IU/day or 2000 IU/day for 12 weeks
Study NCT02376153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABS deployed and active
Description: ABS is deployed onto surgical field and is turned on.
Study NCT02376153 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ABS deployed and NOT active
Description: ABS is deployed onto surgical field and is NOT turned on.
Study NCT01817270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Study NCT02615899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matched: Targeted (specific) balance exercise interventions
Study NCT02615899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mismatched: Untargeted (non-specific) balance exercise interventions
Study NCT02728167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-coagulation of the liver parenchyma with HIFU
Description: 6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
Study NCT01281904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Acupressure
Description: Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
Study NCT01281904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulating Acupressure
Description: Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
Study NCT02550834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair indoors curling training
Description: 8x 90 minutes of training and playing indoors curling in 4 weeks
Study NCT00201110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Skills
Description: Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
Study NCT00201110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Skills
Description: Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
Study NCT01448980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thai Traditional Massage (TTM)
Description: Thai Traditional Massage will receive massage 2 time per week for 6 weeks
Study NCT01448980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: Physical therapy program 2 times per week for 6 weeks.
Study NCT03008369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03008369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT03008369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03561480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
Study NCT03561480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
Study NCT01267500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical therapy
Description: patching or fusion exercises
Study NCT02290769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short guide wire rapid exchange
Description: Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
Study NCT02290769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long guide wire
Description: Use of long wire to guide the cannulation during primary ERCP
Study NCT02536963 — intervention group
Intervention type: DEVICE
Intervention: Pediatric Vision Scanning device
Description: The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
Study NCT02536963 — intervention group
Intervention type: OTHER
Intervention: Reference examination
Description: Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
Study NCT04833218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Test of catecholamines level in moderate traumatic brain injury
Study NCT01070017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT-HAART
Description: For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
Study NCT02817048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube
Study NCT02817048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS without chest tube placement
Description: Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
Study NCT02817048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS with chest tube placement
Study NCT02064257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study NCT03951662 — intervention group
Intervention type: OTHER
Intervention: Alcoholic Hepatitis Group
Description: Alcoholic hepatitis is defined as having a total bilirubin level >3mg/dL and AST level>50U/L
Study NCT03951662 — intervention group
Intervention type: OTHER
Intervention: Heavy Drinking Controls without Hepatitis
Description: Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
Study NCT00515619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial